Literature DB >> 19228938

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

Nicolaus Kröger, Haefaa Alchalby, Evgeny Klyuchnikov, Anita Badbaran, York Hildebrandt, Francis Ayuk, Ulrike Bacher, Oliver Bock, Michael Kvasnicka, Boris Fehse, Axel Zander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19228938     DOI： 10.1182/blood-2008-11-190975

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  33 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Impact of molecular residual disease post allografting in myelofibrosis patients.

Authors:  C Wolschke; A Badbaran; T Zabelina; M Christopeit; F Ayuk; I Triviai; A Zander; H Alchalby; U Bacher; B Fehse; N Kröger
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

3.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

4.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

Review 5.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

Review 6.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

Review 7.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Authors:  Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2021-05-26       Impact factor: 11.528

Review 8.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

9.  Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Authors:  David S Snyder; Joycelynne Palmer; Karl Gaal; Anthony S Stein; Vinod Pullarkat; Firoozeh Sahebi; Nyana Vora; Ryotaro Nakamura; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

10.  Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

Authors:  N Jaekel; G Behre; A Behning; C Wickenhauser; T Lange; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.